Home
Summary of Candidates

Summary of Candidates

VIC works with a wide range of technologies that include live cells, recombinant proteins, small molecules and devices. The Center is currently managing six different technologies at the preclinical stage of development:

  • Small molecule drugs for immune therapy of solid tumors.
  • Fusion protein for immunotherapy of mesothelin-expressing tumors;
  • Islet cell implants that release human proteins to prevent immune rejection;
  • Compact laser adjuvant to enhance immune response to vaccines;
  • Cholera vaccine to provide long-term protection in children;
  • T cell-based vaccine for Q fever that leverages a rapid development process;

In addition, VIC is nurturing seed projects in the areas of personalized vaccines and wound healing.

Research Areas

Candidate Discovery

Personalized cancer vaccine

There has been a resurgence of interest in cancer vaccines in recent years. One of the important new areas of research has been on personalized vaccines for cancer that seek…

Therapeutic Area : Ovarian Cancer
Laboratory : Reeves Laboratory
Photo attribution to : FreeDigitalPhotos.net and jscreations

Proof of Concept Studies

Small molecule inhibitors of CXCL12-CXCR4 interaction

Modification of the body’s immune responses to tumor cells is a highly active area for oncology drug development. The current market for cancer immunotherapy is already a billion dollar market…

Therapeutic Area : Mesothelioma
Laboratory : Chen Laboratory
Photo attribution to : FreeDigitalPhotos.net

Manufacturing and Safety/ Tox

VIC-008 (Jantibody)

VIC-008 represents a new approach to targeted tumor immunotherapy. It enhances tumor-specific CD8+ T cell responses against cancer by tagging tumors with proteins that active immune cells and induce uptake…

Therapeutic Area : Ovarian Cancer
Laboratory : Chen Laboratory
Photo attribution to : National Institutes of Health

Candidate Discovery

No candidates are currently in this development stage.

Proof of Concept Studies

B cells to accelerate wound healing

VIC director Dr. Poznansky, in collaboration with scientists from Emory, discovered that application of B cells isolated from a patient’s blood to a wound site can accelerate healing and reduce…

Therapeutic Area : Advanced Wound Healing
Laboratory : Sîrbulescu Laboratory
Immunoisolating Islet Microbeads

Type 1 diabetes, where the body destroys insulin producing cells, affects about 3 million people in the U.S. Costs of medical management for this disease tops $15 billion per year;…

Therapeutic Area : Type 1 Diabetes
Laboratory : Sremac Laboratory

Manufacturing and Safety/ Tox

No candidates are currently in this development stage.

Candidate Discovery

New Q-fever vaccine using rapid development partnerships

Under a contract with the Defense Threat Reduction Agency, VIC has been developing an approach to rapid vaccine development for Q-fever, a bacterial disease spread from livestock to humans for…

Therapeutic Area : Q fever
Laboratory : Reeves Laboratory
Collaborators : Bowen Lab/ CSU; Bucala Lab/ Yale

Proof of Concept Studies

Laser vaccine adjuvant

Within the $30 billion vaccine industry, technologies to promote intradermal vaccination are rapidly maturing and the first intradermal vaccines have reached the clinic. However, appropriate adjuvants for intradermal vaccination are…

Therapeutic Area : Influenza
Laboratory : Kashiwagi Laboratory
Collaborators : SemiNex Corporation

Manufacturing and Safety/ Tox

OSP conjugate cholera vaccine

Cholera infects 3-5 million people a year and 100,000-120,000 people die from this disease each year, mainly the very young and the elderly. Current oral cholera vaccines provide fairly-effective short-term…

Therapeutic Area : Cholera
Laboratory : Ryan Laboratory
Collaborators : Kovacs Lab/ NIH; Vann Lab/ FDA
Photo attribution to : FreeDigitalPhotos.net and arztsamui